[Featured Stock] Diagnostic Kit Shortage Crisis... Genomictree Rises Over 6%
[Asia Economy Reporter Lee Seon-ae] Amid a surge in COVID-19 cases causing a shortage of diagnostic kits, related stocks are collectively showing strong performance. Genomictree is also linked to diagnostic kit stocks, attracting buying interest and driving its stock price upward.
As of 2:30 PM on the 3rd, the stock is trading at 12,500 KRW, up 5.93% from the previous trading day. During the session, it rose to as high as 12,750 KRW.
Previously, Genomictree signed a global sales and supply agreement for the COVID-19 molecular diagnostic kit 'AccuraDtect SARS-COV-2 RT-qPCR Kit' with Daewoong Pharmaceutical and is jointly collaborating on this effort.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
AccuraDtect diagnoses viral infection by targeting not only the commonly detected N2 gene of the COVID-19 virus but also the leader sequence, which is the most abundant in infected cells. Additionally, it uses real-time polymerase chain reaction (RT-qPCR), a gene amplification technology that explosively increases viral genes for detection, resulting in high accuracy. It is a highly sensitive COVID-19 molecular diagnostic kit that can provide results within 4 hours after sample collection.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
